

Sunshine Biopharma Inc.

(NASDAQ: "SBFM")



Forward-Looking Statements

To the extent that statements in this presentation are not strictly historical, including statements as to revenue projections, future estimates, plans, programs, forecasts, objectives, assumptions, expectations, marketing and sales plans, anticipated revenues, projected market size, beliefs of future performance, business strategy, outlook, future milestones, intentions, goals, future financial conditions, future agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are “forward-looking” and are made pursuant applicable securities laws.

The “forward-looking statements” contained in this presentation are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Sunshine Biopharma Inc. does not intend, and does not assume any obligation, to update these “forward-looking statements” except as required by law. These “forward-looking statements” involve risks and uncertainties relating to, among other things, results of and sale activities, uninsured risks, regulatory changes, availability of production facilities, timeliness of government approvals and the granting of permits and licenses, changes in prices, actual operating and financial performance of facilities, equipment and processes relative to specifications and expectations. Actual results may differ materially from those expressed or implied by such “forward-looking statements.”



About

Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of **Oncology** and **Antiviral** drugs



Product Pipeline

Drug Candidate

Adva-27a

K1.1-mRNA

SBFM-PL4

Area

Oncology

Oncology

Antiviral

Indication

Pancreatic Cancer

MDR Cancer

COVID-19

Time to Phase I

18 – 24 Months

12 – 18 Months

12 – 18 Months

Approved Product

Essential 9™

Area

OTC Supplement

Indication


Amino Acid Deficiency

Time to Market


Currently on the Market

Oncology Drug Development (Adva-27a)

- ❑ **Adva-27a** is a chemotherapy small molecule (Topo II inhibitor)
- ❑ **Adva-27a** has the uncommon property of being effective against **Multidrug Resistant Cancer**
- ❑ All **Patents** pertaining to **Adva-27a** are owned by the Company
- ❑ **Patent** coverage until **2034**




Adva-27a Kills Multidrug Resistant Cancer Cells



Adva-27a Kills Multidrug Resistant Breast Cancer Cells, Pancreatic Cancer Cells, Small-Cell Lung Cancer Cells, and Uterine Sarcoma Cells


Oncology Drug Development (K1.1 mRNA)

- ❑ K1.1 is an mRNA that encodes an inhibitor of a transcription factor essential for initiation of cell division
- ❑ We have recently shown that **K1.1 mRNA** is capable of destroying cancer cells in vitro including breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2)
- ❑ Tests conducted using non-transformed (normal) cells (HMEC) showed that these **K1.1 mRNA** had little or no cytotoxic effects
- ❑ **K1.1 mRNA** is readily adaptable for delivery into patients using the mRNA vaccine technology
- ❑ In April 2022, we filed a provisional patent application in the United States covering the **K1.1 mRNA** molecules and uses thereof
- ❑ Next, we plan to conduct mice xenograft studies to test the efficacy of **K1.1 mRNA** in vivo



Antiviral Drug Development (SBFM-PL4)

- ❑ We embarked on the development of a **treatment for COVID-19** in April 2020
- ❑ Since then, three vaccines (Pfizer's, Moderna's, and Johnson & Johnson's), two antibody treatments (Regeneron's, and Eli Lilly's), one injectable (Gilead's Remdesivir), and two pills (Pfizer's Paxlovid, and Merck's Molnupiravir) have emerged
- ❑ Our treatment, **SBFM-PL4**, targets a different part of the virus, the viral protease responsible for suppression of the immune system
- ❑ We are developing this in collaboration with the University of Arizona
- ❑ Testing in transgenic mice is currently underway



Approved OTC Product – Essential 9™

- ❑ Along the way, we developed **Essential 9™**
- ❑ **Essential 9™** is a capsule that contains the 9 Amino Acids that the human body cannot make. These are called Essential Amino Acids
- ❑ **Deficiency** in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain, weakened immune system, and reduced general wellness
- ❑ **Essential 9™** is approved by Health Canada under **NPN 80089663**
- ❑ The Company currently sells **Essential 9™** through Amazon in the US and Canada. Also available in pharmacies in Montreal (Canada)
- ❑ We are currently planning a large-scale marketing effort



Capitalization

Outstanding Common Shares	18,885,632
Outstanding Preferred Shares	None
Outstanding Warrants	1,764,594 Exercisable at \$2.22
Outstanding Warrants	9,725,690 Exercisable at \$3.76
Outstanding Options	None
Outstanding Debt	None
Cash on Hand	\$41,600,000
Current Stock Price	\$_____ Per Share
Average Daily Volume	1,081,552 Shares



Management

Steve N. Slilaty, Ph.D.	Molecular Biologist	Univ. of Arizona	Director & CEO
Abderrazzak Merzouki, Ph.D.	Virologist	Institut Armand-Frappier	Director & COO
Rabi Kiderchah, MD	Physician	Univ. de Montreal	Director
Andrew Keller, MD	Physician	Ohio State University	Director
David Nathan, BA	Economist	Boston University	Director
Camille Sebaaly, BSc	Engineering	SUNY Buffalo	CFO

Sunshine Biopharma Inc.

(NASDAQ: "SBFM")

Thank You for Your Attention!

www.sunshinebiopharma.com

